Sanofi SA vs Teradyne, Inc. — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Teradyne, Inc. trades at $374.62 (market cap $52.25B). The key difference: Sanofi SA is far larger — about 2× Teradyne, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | TER | |
|---|---|---|
Market Cap | $104.83B | $52.25B |
Sector | Health | Technology |
52-Week High | $52.34 | $483.84 |
52-Week Low | $41.33 | $90.15 |
Enterprise Value | $121.32B | $52.08B |
Dividend Yield | 5.5% | 0.16% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →